Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03412799
Other study ID # CL-SBP-101-03
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date June 4, 2018
Est. completion date February 28, 2022

Study information

Verified date May 2022
Source Panbela Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label phase 1A/1B study to assess the safety, tolerability and pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal adenocarcinoma and to identify a recommended phase 2 dose. The study will also assess preliminary efficacy of the 3-drug treatment combination.


Description:

The study will be conducted in two phases: dose escalation and expansion. Up to three dose levels of SBP-101 will be assessed in up to 18 subjects during dose escalation. The expansion phase of the study will consist of 10 additional subjects who will receive the recommended dose of SBP-101 combined with nab-paclitaxel and gemcitabine.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date February 28, 2022
Est. primary completion date February 28, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma. Patients with pancreatic acinar cell carcinoma may also be included. - Is previously untreated for metastatic pancreatic ductal adenocarcinoma, was diagnosed within the past 3 months, and is expected to receive standard treatment with gemcitabine and nab-paclitaxel. - Measurable disease on CT or MRI scan by RECIST v 1.1 criteria. - ECOG Performance Status 0 or 1. - Adult, age = 18 years, male or female. - Females of child-bearing potential must have a negative serum pregnancy test within 14 days prior to start of study treatment and must use an adequate method of contraception during the study. All sexually active males must also use an adequate method of contraception during the study. Female subjects will be considered to be of childbearing potential unless they are postmenopausal (at least 12 months of consecutive amenorrhea, without other known or suspected cause) and over 55 years old or have been sterilized surgically (i.e., bilateral tubal ligation, hysterectomy or bilateral oophorectomy, all with surgery at least one month before dosing). - Adequate bone marrow, hepatic, renal and coagulation function as defined by the following: 1. Absolute neutrophil count =1.5 x 109/L 2. Hemoglobin =9.0 g/dL (90 g/L) 3. Platelets =100 x 109/L 4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 x upper limit of normal (ULN) (if no hepatic metastases). If hepatic tumor involvement, AST and ALT =5 x ULN. 5. Bilirubin =1.5 x ULN 6. Prothrombin time (PT) / international normalized ratio (INR) =1.5 x ULN if not on anti-coagulants 7. Calculated creatinine clearance >50 mL/min using the Cockcroft and Gault equation - QTc interval = 470 msec at Baseline. - Life expectancy = 3 months. - Willing and able to provide written informed consent: voluntary agreement to participate in the study following disclosure of risks and procedures required, including possibility of onset of exocrine pancreatic insufficiency with subsequent requirement for life-long pancreatic enzyme replacement. Exclusion Criteria: - Evidence of severe or uncontrolled systemic disease or any concurrent condition that, in the opinion of the Investigator or Medical Monitor, makes it undesirable for the subject to participate in the study or that would jeopardize compliance with the protocol. Subjects with pre-existing well-controlled diabetes are not excluded. - Medical or psychiatric conditions that compromise the subject's ability to give informed consent or to complete the protocol or a history of non-compliance - Presence of islet-cell or pancreatic neuroendocrine tumor or mixed adenocarcinoma-neuroendocrine carcinoma - Have symptomatic central nervous system (CNS) malignancy or metastasis. Screening of asymptomatic subjects without history of CNS metastases is not required. - Serum albumin <30 g/L (3.0 g/dL) - Evidence of deep vein thrombosis or pulmonary embolism or other thromboembolic event during screening - Presence of known active bacterial, fungal, or viral infection requiring systemic therapy - Known active infection with human immunodeficiency virus (HIV), hepatitis B or C - Presence of interstitial lung disease, pulmonary fibrosis, or pulmonary hypersensitivity reaction - Myocardial infarction within the last 12 months, severe/unstable angina, symptomatic congestive heart failure New York Heart Association (NYHA) class III or IV - Maldigestion/malabsorption syndrome pre-dating the diagnosis of pancreatic cancer. - Pregnant or lactating - Major surgery within 4 weeks of the start of study treatment, without complete recovery - Known hypersensitivity to any component of study treatments - Participation in any other clinical investigation within 4 weeks of receiving the first dose of study drug - Subjects taking metformin. Diabetics on treatment with metformin, or any other derivative thereof, must discontinue it while on study. (Other diabetic medications are allowed.)

Study Design


Intervention

Drug:
SBP-101
Administered as subcutaneous (SC) injection, escalating dose cohorts
nab-paclitaxel
Administered as intravenous (IV) infusion
Gemcitabine Injection
Administered as intravenous (IV) infusion

Locations

Country Name City State
Australia Blacktown Cancer & Haematology Centre Blacktown New South Wales
Australia Austin Health Heidelberg Victoria
Australia Ashford Cancer Centre Kurralta Park South Australia
Australia John Flynn Private Hospital Tugun Queensland
United States University of Florida Gainesville Florida
United States Scripps MD Anderson Cancer Center La Jolla California
United States University of Rochester Medical Center Rochester New York

Sponsors (1)

Lead Sponsor Collaborator
Panbela Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recommended dose of SBP-101 Up to 12 months following the first dose of treatment
Secondary Number of subjects with adverse events as a measure of safety and tolerability Up to 24 months following the first dose of treatment
Secondary Tumor response will be evaluated on RECIST definitions Every 8 weeks during treatment assessed up to 24 months
Secondary Area under the plasma concentration versus time curve (AUC) for all three drugs Day 1 of Cycle 1
Secondary Peak plasma concentration (Cmax) for all three drugs Day 1 of Cycle 1
See also
  Status Clinical Trial Phase
Terminated NCT02495896 - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT02005315 - A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer Phase 1
Completed NCT01453153 - Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer Phase 1/Phase 2
Completed NCT01064622 - Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Phase 1/Phase 2
Completed NCT00095966 - Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Completed NCT02178436 - Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT01647828 - A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Phase 1/Phase 2
Completed NCT01191684 - Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer Phase 1
Terminated NCT01555489 - Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca Phase 2
Completed NCT01232829 - Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer Phase 2
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00735917 - Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer Phase 2
Completed NCT02896907 - Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Early Phase 1
Completed NCT02307539 - Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer N/A
Completed NCT02050178 - Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer Phase 1
Completed NCT01488552 - Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT01222689 - Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Completed NCT00397787 - Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine Phase 2
Completed NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Phase 1